Okay, let's tackle this question. The question is about why atropine is added with diphenoxylate. I remember that diphenoxylate is an opioid used for diarrhea. Opioids can cause side effects like drowsiness, addiction, etc. Atropine is an anticholinergic. Maybe they add atropine to counteract something?

Wait, I think the main reason for combining them is to prevent abuse. Because if someone tries to crush the pills to snort or inject them, the atropine would cause anticholinergic side effects like dry mouth, hallucinations, which are unpleasant and deter misuse. That makes sense. So the correct answer is probably about preventing abuse or misuse.

Looking at the options, the correct answer should be something like "To prevent abuse by deterring intravenous administration." Now, the other options might include things like enhancing efficacy, reducing side effects, or treating another symptom. But those are incorrect because atropine isn't there to enhance the effect of diphenoxylate. It's specifically there as a deterrent. Let me confirm: yes, in the combination drug (like Lomotil), atropine is included in a dose that's not enough to affect the antidiarrheal action but enough to cause side effects if the pills are misused. So the other options would be wrong because they don't address the abuse deterrent purpose.

**Core Concept**
The combination of diphenoxylate (an opioid antidiarrheal) and atropine (an anticholinergic) is pharmacologically designed to prevent drug abuse. Atropine’s role is not therapeutic for diarrhea but serves as a deterrent against misuse.

**Why the Correct Answer is Right**
Atropine is added in sub-therapeutic doses to induce anticholinergic side effects (e.g., dry mouth, tachycardia, hallucinations) if the drug is crushed, snorted, or injected. This discourages intravenous misuse, which is common with opioids. Diphenoxylate alone is a Schedule II controlled substance due to abuse potential; atropine’s inclusion reduces this risk by making abuse unpleasant or dangerous.

**Why Each Wrong Option is Incorrect**
**Option A:** *To enhance antidiarrheal efficacy* — Incorrect. Atropine does not amplify diphenoxylate’s primary effect on intestinal motility.
**Option B:** *To reduce opioid-induced constipation* — Incorrect. Atropine exacerbates constipation by inhibiting gastrointestinal motility.
**Option C:** *To treat bradycardia caused by opioids* — Incorrect. Diphenoxylate does not cause bradycardia; atropine is not used for heart rate modulation in this context.

**Clinical Pearl / High-Yield Fact**
The atropine-diphenoxylate combination (e.g., Lomotil) is a classic example of a drug formulation designed to deter abuse. Always associate atropine in this context with **abuse prevention**, not therapeutic synergy.

**Correct Answer: C. To prevent abuse by deterring intravenous administration**

✓ Correct Answer: C. Decrease abuse potential